Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452433 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3MAOBKCNH2 | |
| SCHEMBL13134072 | 0.83 | MAOB (0.47) | SLC6A4SLC6A2SLC6A3MAOBKCNH2 | |
| SCHEMBL6942011 | 0.82 | KCNH2 (0.51) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5456472 | 0.82 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3MAOB | |
| SCHEMBL5456466 | 0.82 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3MAOB | |
| SCHEMBL9562401 | 0.75 | MAOB (0.53) | SLC6A4MAOB | |
| SCHEMBL21622788 | 0.74 | MAOB (0.55) | SLC6A4SLC6A2SLC6A3MAOBTAAR1 | |
| SCHEMBL9178268 | 0.73 | MAOB (0.54) | MAOBTAAR1 | |
| SCHEMBL9133245 | 0.71 | MAOB (0.53) | SLC6A4SLC6A2SLC6A3MAOBKCNH2 | |
| SCHEMBL10382747 | 0.71 | MAOB (0.53) | SLC6A4SLC6A2SLC6A3MAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | SLC6A4 1446/4885SLC6A2 1034/4885SLC6A3 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.